Product Description
Morphine Sulfate Plus Naltrexone Hydrochloride ER for pain (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00415597)
Mechanisms of Action: OPR Binder, OPR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Chronic Pain|Osteoarthritis, Hip|Back Pain|Morphine Dependence|Neuralgia
Phase 2: Morphine Dependence
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00751478 |
MSIR | P2 |
Completed |
Morphine Dependence |
2007-05-01 |
2019-03-18 |
Treatments |
|
NCT00415597 |
ALO-KNT-302 | P3 |
Completed |
Neuralgia|Chronic Pain|Morphine Dependence|Back Pain |
2008-03-01 |
2019-03-21 |
Treatments |
|
NCT00420992 |
ALO-KNT-301 | P3 |
Completed |
Chronic Pain|Osteoarthritis, Hip |
2007-11-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|